VORONOI is a research and development specialist focused on developing new drug candidates, with a business model centered on licensing out (L/O) drug candidates before early clinical stages (Phase 1, Phase 2a). The company concentrates on the field of targeted therapies, which treat diseases by selectively binding to and regulating the function of disease-causing kinases from over 550 kinases responsible for intracellular signal transduction.

KiHUBMAP : The greatest strength of VORONOI's library is that it has constructed full panel profiling data and drug efficacy data for each of the 468 kinase compounds. Therefore, when the relationship between a specific molecular target and a disease is revealed in academic studies, VORONOI can swiftly identify lead compounds by searching its own database for compounds selectively binding to the target. Currently, VORONOI has built a kinase profiling database for over 3,500 compounds, and around 500 new compounds are added to the database annually. This extensive compound structure-kinase selection database is expected to significantly enhance Borono's production efficiency by reducing the time required for this process. KiHUB PREDICTOR is a molecular design tool that utilizes the KiHUB MAP and KiHUB™ DB to predict the activity and selectivity values of virtually designed compounds, enabling efficient lead compound discovery. Departs from traditional molecular fingerprint-based methods of compound recognition and instead employs a recognition model based on a Messenger Passing Neural Network, which identifies atomic-level units. This enhances the accuracy of compound and protein recognition. Additionally, to assess the binding affinity of compounds to target kinases, the tool applies a Variational Auto-Encoder-based Kinase Inhibitor Drug-Like compound generation model. By utilizing a self-organizing latent map, it provides higher selectivity based on kinase target specificity.

Public

Biotech